科笛-B(02487.HK)公布两产品内地III期临床试验结果

阿斯达克财经11-28

科笛-B(02487.HK) 公布，其治疗雄激素性脱发产品CU-40102以及用于皮肤表皮手术的CU-30101的中国III期临床试验结果在全国美容皮肤科学大会(CDA年会)上公布。其中，CU-40102组的受试者的顶部秃发目标区域内的总毛发计数及终毛计数相比于基线改善均显著优于安慰剂组，达到主要终点指标和主要的次要终点指标，而且疗效从第12周起开始展现。至于CU-30101，其临床试验结果显示...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2486355335?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230602115202398_s.jpg","is_english":false,"pubTime":"2024-11-28 12:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486355335","market":"hk","top_or_hot":-1,"title":"科笛-B(02487.HK)公布两产品内地III期临床试验结果","media":"阿斯达克财经","content":"<div>\n<p>科笛-B(02487.HK) 公布，其治疗雄激素性脱发产品CU-40102以及用于皮肤表皮手术的CU-30101的中国III期临床试验结果在全国美容皮肤科学大会(CDA年会)上公布。其中，CU-40102组的受试者的顶部秃发目标区域内的总毛发计数及终毛计数相比于基线改善均显著优于安慰剂组，达到主要终点指标和主要的次要终点指标，而且疗效从第12周起开始展现。至于CU-30101，其临床试验结果显示...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1400204/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科笛-B(02487.HK)公布两产品内地III期临床试验结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科笛-B(02487.HK)公布两产品内地III期临床试验结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-28 12:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1400204/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>科笛-B(02487.HK) 公布，其治疗雄激素性脱发产品CU-40102以及用于皮肤表皮手术的CU-30101的中国III期临床试验结果在全国美容皮肤科学大会(CDA年会)上公布。其中，CU-40102组的受试者的顶部秃发目标区域内的总毛发计数及终毛计数相比于基线改善均显著优于安慰剂组，达到主要终点指标和主要的次要终点指标，而且疗效从第12周起开始展现。至于CU-30101，其临床试验结果显示...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1400204/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1400204/latest-news/AAFN","article_id":"2486355335","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230602115202398_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486355335","pubTimestamp":1732766460,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"科笛-B(02487.HK) 公布，其治疗雄激素性脱发产品CU-40102以及用于皮肤表皮手术的CU-30101的中国III期临床试验结果在全国美容皮肤科学大会(CDA年会)上公布。其中，CU-40102组的受试者的顶部秃发目标区域内的总毛发计数及终毛计数相比于基线改善均显著优于安慰剂组，达到主要终点指标和主要的次要终点指标，而且疗效从第12周起开始展现。至于CU-30101，其临床试验结果显示CU-30101与Pliaglis®镇痛疗效相当，达到主要终点。两款产品的药品上市许可申请已在今年获国家药监局受理。(vc/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1576":"医药外包概念","BK1161":"生物科技","BK1141":"生命科学工具和服务","03347":"泰格医药","BK1583":"高瓴概念","02487":"科笛-B"},"translate_title":"Kedi-B (02487. HK) announces the results of phase III clinical trials of two products in mainland China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02487":1,"03347":1},"content_text":"科笛-B(02487.HK) 公布，其治疗雄激素性脱发产品CU-40102以及用于皮肤表皮手术的CU-30101的中国III期临床试验结果在全国美容皮肤科学大会(CDA年会)上公布。其中，CU-40102组的受试者的顶部秃发目标区域内的总毛发计数及终毛计数相比于基线改善均显著优于安慰剂组，达到主要终点指标和主要的次要终点指标，而且疗效从第12周起开始展现。至于CU-30101，其临床试验结果显示CU-30101与Pliaglis®镇痛疗效相当，达到主要终点。两款产品的药品上市许可申请已在今年获国家药监局受理。(vc/u)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486355335"}